Thermo Fisher Scientific Total Revenue increased by 6.2% to $11.01B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.2%, from $10.36B to $11.01B. Over 3 years (FY 2021 to FY 2024), Total Revenue shows relatively stable performance with a 3.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.27B | $9.33B | $10.70B | $11.82B | $10.97B | $10.68B | $11.45B | $10.71B | $10.69B | $10.57B | $10.89B | $10.35B | $10.54B | $10.60B | $11.40B | $10.36B | $11.01B |
| QoQ Change | — | +0.6% | +14.7% | +10.4% | -7.2% | -2.7% | +7.2% | -6.5% | -0.2% | -1.1% | +3.0% | -5.0% | +1.9% | +0.5% | +7.5% | -9.0% | +6.2% |
| YoY Change | — | — | — | — | +18.3% | +14.4% | +7.0% | -9.4% | -2.6% | -1.0% | -4.9% | -3.4% | -1.4% | +0.2% | +4.7% | +0.2% | +6.2% |
| Segment | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Service revenues | $4.48B | $4.39B | $4.38B | $4.45B | $4.63B | $4.38B | $4.63B | $4.73B |
| Consumables | $4.37B | $4.33B | $4.36B | $4.38B | $4.52B | $4.35B | $4.68B | $4.72B |
| Instruments | $2.04B | $1.63B | $1.80B | $1.77B | $2.25B | $1.63B | $1.81B | $1.56B |
| Total | $10.89B | $10.35B | $10.54B | $10.60B | $11.40B | $10.36B | — | $11.01B |
| Segment | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Laboratory Products and Biopharma Services | — | — | — | — | — | — | $5.97B | $6.04B |
| Life Sciences Solutions | $2.47B | $2.29B | $2.36B | $2.39B | $2.60B | $2.34B | $2.59B | $2.64B |
| Analytical Instruments | $2.04B | $1.69B | $1.78B | $1.81B | $2.19B | $1.72B | $1.89B | $1.72B |
| Specialty Diagnostics | $1.11B | $1.11B | $1.12B | $1.13B | $1.16B | $1.15B | $1.17B | $1.14B |
| Laboratory Productsand Services | $5.72B | $5.72B | $5.76B | $5.74B | — | — | — | — |
| Total | $10.89B | $10.35B | $10.54B | $10.60B | $11.40B | $10.36B | — | $11.01B |
Laboratory Productsand Services was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
| Segment | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| North America | $5.60B | $5.52B | $5.53B | $5.59B | $5.87B | $5.51B | $5.69B | $5.71B |
| Europe | $2.84B | $2.62B | $2.66B | $2.69B | $2.89B | $2.62B | $3.01B | $2.96B |
| Asia-Pacific | $2.07B | $1.86B | $1.97B | $1.92B | $2.20B | $1.89B | $2.01B | $1.97B |
| Other regions | $367.00M | $346.00M | $379.00M | $397.00M | $439.00M | $337.00M | $415.00M | $372.00M |
| Total | $10.89B | $10.35B | $10.54B | $10.60B | $11.40B | $10.36B | — | $11.01B |